Cover Image
市場調查報告書

美國的MA (醫療事務) 部門的評估:腎細胞癌

Medical Affairs Reputations: Renal Cell Carcinoma (US)

出版商 FirstWord 商品編碼 358494
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的MA (醫療事務) 部門的評估:腎細胞癌 Medical Affairs Reputations: Renal Cell Carcinoma (US)
出版日期: 2016年04月01日 內容資訊: 英文
簡介

本報告以腎細胞癌治療藥的主要8個產品相關的醫療事務 (MA) 團隊上,美國的100名癌症專門醫生為對象加以調查,彙整其對各公司團隊的效能及滿意度評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析。

對象的企業·品牌

  • Afinitor (Everolimus:Novartis)
  • Avastin (Bevacizumab:Genentech)
  • Inlyta (Axitinib :Pfizer)
  • Opdivo (niborumabu:BMS)
  • Proleukin (Aldesleukin:Prometheus)
  • Sutent (Sunitinib:Pfizer)
  • Torisel (temushirorimusu:Pfizer)
  • Votrient (Pazopanib:Novartis)

調查·分析內容範例

  • MA隊的利用方法·頻率
  • 一般認為最重要的服務
  • 聯繫的頻率和偏好的途徑
  • 醫生對各團隊的印象
  • 各隊伍的效能·滿意度排行榜:12項
  • 醫生的需求與服務的改善點
目錄
Product Code: 596200647

Opdivo's medical affairs team working overtime to engage oncologists. Is it paying off?

Opdivo's medical affairs team has been busy. Since late 2015, when the Anti-PD-1 monoclonal antibody got FDA approval for renal cell carcinoma (RCC) treatment, they've been one of the most active teams in the US market.

Is it paying off?

Find out how oncologists rate Opdivo's team, and how the teams for 7 other major RCC treatments measure up, in Medical Affairs Reputations: RCC.

You'll learn whether your team is giving oncologists the services they want, whether they're satisfied with your performance, and where you need the most improvement.

Answering Key Questions about Medical Affairs Teams for 8 Major RCC Brands

  • Afinitor (everolimus; Novartis): Are oncologists more satisfied with Afinitor's team or Votrient's?
  • Avastin (bevacizumab; Genentech): Which brand's team is tied with Avastin's for overall quality of interactions?
  • Inlyta (axitinib; Pfizer): Does Inlyta's team outperform Votrient's?
  • Opdivo (nivolumab; BMS): Performance scores for Opdivo's team are mostly middle of the pack, but it excels in two areas. Which two?
  • Proleukin (aldesleukin; Prometheus): Proleukin's team gets high performance and satisfaction scores in most areas. How does it rank for overall quality of interactions?
  • Sutent (sunitinib; Pfizer): Sutent's team is one of the leading teams in Europe. How is it doing in the US?
  • Torisel (temsirolimus; Pfizer): Is Torisel's team better at responding promptly to inquiries or providing scientific and product information?
  • Votrient (pazopanib; Novartis): Has Votrient's team interacted with more oncologists than Afinitor's, Avastin's, or Inlyta's in the last 6 months?

Top Takeaways

  • Huge lead for #1 team: Despite average performance and satisfaction scores in several areas, its overall quality rating is more than double that of its closest competitor.
  • Stiff competition downmarket: Rated for overall quality of interactions, a mere 2 points separate the 2nd place team from the 5th place team.
  • Unmet need in the market: The way oncologists use medical affairs teams right now suggests high levels of unmet need in the market.
  • Oncologists hungry for information: They say the most important medical affairs services involve providing information and clinical support.
  • Solid performance: Scores are moderately high to high-especially in important areas. Some of the highest go to the team with the lowest overall quality rating.
  • Several areas need improvement: Most teams need to improve satisfaction in 3 to 4 of the 6 services most important to oncologists.
  • Satisfaction is high, but not across the board: Several teams earn high scores in most areas, but others lag.
  • Oncologists prefer meeting face-to-face: In-person interaction types rank higher than electronic interactions and phone calls, although email is fairly well tolerated.

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams-answering important questions like:

What do oncologists need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with oncologists?
  • How do oncologists rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to oncologists?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Oncologists

We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with NSCLC in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the last 6 months.

We conducted the survey between March 2nd and March 17th, 2016

Back to Top